Sunday, January 2

FDA Approves Tysabri: "Because of positive data from clinical trials, the FDA approved Tysabri—formerly called Antegren®—after only one year of study. Usually, two years of trials are required before approving a new drug.Trial results a 66% reduction in the relapse rate of MS symptoms in patients studied when compared with placebo."